ProCE Banner Activity

PURPOSE-1: Phase III Trial of Twice-Yearly LEN vs Daily FTC/TAF or FTC/TDF for HIV PrEP in Cisgender Women

Conference Coverage
Slideset

In PURPOSE-1 study in South Africa and Uganda, twice-yearly PrEP with SC lenacapavir resulted in no HIV infections and appeared to have superior efficacy to daily PrEP with oral FTC/TDF. 

Released: July 26, 2024

Expiration: July 25, 2025

Share

Faculty

Angela Davies

Angela Davies, MD

Assistant Professor of Medicine
UC Davis Cancer Center
Sacramento, CA

Provided by

Provided by Clinical Care Options, LLC in partnership with the International AIDS Society

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS

ProCE Banner